AMH Predicts Benefit of Chemotherapy in Young Breast Cancer Patients

A recent study published in the Annals of Oncology has shed light on the effectiveness of chemotherapy plus endocrine therapy (CET) compared to endocrine therapy (ET) alone in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. The research focused on women under the age of 55 with a recurrence score (RS) of 25 or less, a measure used to predict the likelihood of cancer recurrence. The study found that anti-Müllerian hormone (AMH) levels may serve as a valuable predictor in determining the most beneficial treatment approach for these patients.

According to the study, AMH levels were found to be associated with the effectiveness of CET versus ET alone. The researchers discovered that women with higher AMH levels may benefit more from CET, while those with lower AMH levels may achieve similar outcomes with ET alone. This information could aid healthcare professionals in making more informed treatment decisions for premenopausal women with hormone receptor-positive breast cancer, potentially leading to improved patient outcomes.

The findings of this study have significant implications for the treatment of hormone receptor-positive breast cancer in premenopausal women. By identifying the role of AMH in predicting the benefit of CET versus ET alone, healthcare professionals can develop more personalized treatment plans, tailoring the approach to each patient's unique needs and characteristics. Further research is necessary to confirm these findings and explore their potential applications in clinical practice.